Wellinks Adds Douglas Wenners to Board of Directors

Wenners Brings 25 Years of Health Plan Experience in Growth, Strategy, and Innovation

NEW HAVEN, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) — Wellinks, the leading digital healthcare company offering virtual Chronic Obstructive Pulmonary Disease (COPD) management for health plans and value-based care providers, today announced Douglas Wenners has joined its board of directors as an independent director. Wenners brings over 25 years of experience working with health plans, and he is a strong advocate for home-based care for people living with serious illnesses.

Prior to his current role, Wenners served as the CEO and co-founder of Prospero Health, a home-based medical care provider. Previously, he served as the CEO of Privia Health and significantly grew the company’s market presence by more than 25 percent. He also held various executive leadership positions at Anthem, where he designed the largest pay for value program in the country and redesigned the company’s public exchange business after the passage of the Affordable Care Act.

“COPD is the third leading cause of death by chronic disease in the United States, but there’s a lot of potential to keep people healthy at home,” said Alex Waldron, Wellinks CEO. “Doug’s skills and experience will accelerate our ability to fulfill our mission of helping people with COPD live fully and breathe freely.”

“COPD is a uniquely challenging issue to manage, but Wellinks has fundamentally changed the ability to engage this population,” said Wenners. “I look forward to working with more payers and providers across the country to bring more value and improve outcomes for those with COPD.”

Wellinks’ Board of Directors is chaired by HighCape Capital’s Kevin Rakin, and also includes Morningside’s Stephen Bruso, Laniakea and OTV’s Henry Weinstein, and Wellinks’ CEO Alex Waldron.

About Wellinks
Wellinks is on a mission to help those with chronic obstructive pulmonary disease (COPD) live fully and breathe freely. COPD is the third leading cause of death by chronic disease in the U.S. and the fifth most costly chronic disease. With its personalized, virtual-first COPD management system, Wellinks breaks down barriers for patients, providing the evidence-based care they need and deserve outside the four walls of the clinic. Wellinks supports patients through virtual care, including pulmonary rehabilitation, health coaching, and monitoring aided by connected devices and an easy-to-use smartphone app. Based in New Haven, Connecticut, Wellinks is led by a team of digital health veterans and backed by top investment firms including Morningside, HighCape Capital, Connecticut Innovations, and Benslie. For more information, visit www.wellinks.com and follow on Twitter (@WellinksHealth) and LinkedIn.

Press Contact:
Caitlin Krutsick
wellinks@crosscutstrategies.com

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

13 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

16 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

16 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

16 hours ago